NICE Expands Cladribine Access for MS Patients
- In a significant growth for multiple sclerosis (MS) treatment, the National Institute for Health and Care Excellence (NICE) has issued guidance recommending cladribine (Mavenclad, merck Serono) for adults...
- The NICE guidance specifies that cladribine is now a viable option for adults experiencing active RRMS, particularly when high-efficacy disease-modifying therapies (DMTs) are being considered.
- One of the key advantages of cladribine is its convenient dosing schedule.
NICE Recommends Cladribine for Relapsing-Remitting Multiple Sclerosis Treatment
Table of Contents
- NICE Recommends Cladribine for Relapsing-Remitting Multiple Sclerosis Treatment
- Cladribine (Mavenclad) for RRMS: Your Questions Answered
- What is Cladribine (Mavenclad)?
- Who is Cladribine for?
- What are the benefits of Cladribine?
- How does Cladribine work?
- How effective is Cladribine?
- How does the dosing schedule of Cladribine compare to other RRMS treatments?
- How does Cladribine impact pregnancy planning?
- What was the CLARITY trial?
- What is NICE’s role in Cladribine’s availability?
- How many people are expected to benefit from NICE’s updated proposal?
- Summary of Cladribine (mavenclad)
In a significant growth for multiple sclerosis (MS) treatment, the National Institute for Health and Care Excellence (NICE) has issued guidance recommending cladribine (Mavenclad, merck Serono) for adults in England who are battling relapsing-remitting multiple sclerosis (RRMS). This decision positions the NHS as the first healthcare system in Europe to broadly offer this at-home tablet to patients with active MS.
The NICE guidance specifies that cladribine is now a viable option for adults experiencing active RRMS, particularly when high-efficacy disease-modifying therapies (DMTs) are being considered.
Cladribine: A Convenient Option for RRMS Patients
One of the key advantages of cladribine is its convenient dosing schedule. It requires only 20 days of dosing over a span of 4 years. This presents a stark contrast to many existing therapies that demand frequent hospital infusions, self-injections, or extensive monitoring.
This convenience translates to significant lifestyle benefits for patients. They can minimize travel to medical appointments, maintain their employment, and make better-informed family planning decisions. As the regulator pointed out, ”Patients planning a pregnancy can also safely conceive in years 3 and 4 of their treatment cycle as cladribine is administered in short courses over 2 years.”
Laura Thomas, head of policy at the MS Society, expressed her support for the guidance, stating:
Cladribine is self-administered, so this decision could particularly benefit people who’d struggle to go into hospital regularly, like younger working-age adults.
She further added,
It will also benefit patients considering starting a family, as it’s safe to get pregnant 6 months after the final course of treatment – which is less restrictive than many other DMT options.
The Impact of Cladribine on Relapse reduction
multiple sclerosis affects over 150,000 individuals in the UK, with 85%-90% diagnosed with the relapsing form. Cladribine functions by targeting T and B cells, which are responsible for damaging the myelin sheath in MS patients.
NICE had previously recommended cladribine for highly active and rapidly evolving severe forms of MS.This updated proposal broadens access to a larger patient population,with approximately 2000 individuals expected to benefit within the next 3 years.
Clinical Evidence Supporting Cladribine
Clinical trial data demonstrates that cladribine effectively reduces relapses and slows down disability progression compared to placebo. Indirect comparisons suggest that the relapse rate associated with cladribine is comparable to that of ocrelizumab and ofatumumab, which are frequently prescribed treatments for active RRMS.
The CLARITY trial, a randomized, double-blind study involving 1326 patients with active and highly active RRMS, compared 3.5 mg/kg and 5.25 mg/kg doses of cladribine with a placebo. The results indicated a 58% reduction in the average annual relapse rate. Remarkably, nearly 80% of patients receiving cladribine experienced no relapses.MRI scans further revealed that patients undergoing treatment developed 7.5 times fewer new brain lesions compared to those receiving a placebo.
NICE emphasized that cladribine offers clinical benefits comparable to existing treatments while considerably decreasing the need for hospital visits and clinical monitoring time.
Professor James Palmer, NHS medical director for specialised commissioning, stated that this decision would “free up clinical time, helping clinicians see more patients and boosting NHS productivity”.
Cladribine (Mavenclad) for RRMS: Your Questions Answered
Cladribine, also known as Mavenclad, is an oral medication recently recommended by the National Institute for Health and Care Excellence (NICE) for treating relapsing-remitting multiple sclerosis (RRMS). This Q&A provides complete information about cladribine, its benefits, and its implications for individuals living with RRMS.
What is Cladribine (Mavenclad)?
cladribine is a disease-modifying therapy (DMT) used to treat relapsing-remitting multiple sclerosis (RRMS). It is administered as a tablet taken at home. NICE (National Institute for Health and Care Excellence) has recommended it,making the NHS the first healthcare system in Europe to broadly offer it as an at-home treatment for active MS.
Who is Cladribine for?
Cladribine is a viable option for adults experiencing active RRMS, especially when high-efficacy disease-modifying therapies (DMTs) are being considered.
What are the benefits of Cladribine?
Convenient Dosing Schedule: Cladribine only requires 20 days of dosing over a 4-year period.
Reduced Hospital Visits: Patients can minimize travel to medical appointments and reduce clinical monitoring time.
Lifestyle Benefits: Easier to maintain employment and make informed family planning decisions.
Pregnancy Planning: Patients can safely conceive in years 3 and 4 of their treatment cycle because cladribine is given in short courses over 2 years.
How does Cladribine work?
Cladribine targets T and B cells, which are responsible for damaging the myelin sheath in MS patients. By targeting thes cells, cladribine helps to reduce relapses and slow down the progression of disability.
How effective is Cladribine?
Clinical trial data has shown that cladribine:
Reduces relapses effectively compared to placebo. The CLARITY trial demonstrated a 58% reduction in the average annual relapse rate
Slows down disability progression.
Indirect comparisons suggest that the relapse rate associated with cladribine is comparable to that of ocrelizumab and ofatumumab.
The CLARITY trial showed that nearly 80% of patients receiving cladribine experienced no relapses.Also, MRI scans showed that patients undergoing treatment developed 7.5 times fewer new brain lesions compared to those receiving a placebo.
How does the dosing schedule of Cladribine compare to other RRMS treatments?
Cladribine is more convenient due to its infrequent dosing schedule of only 20 days over 4 years, while many existing therapies require frequent hospital infusions, self-injections, or extensive monitoring.
How does Cladribine impact pregnancy planning?
Cladribine allows patients to safely conceive in years 3 and 4 of their treatment cycle, offering more flexibility compared to other DMT options. Pregnancy is considered safe 6 months after the final course of treatment.
What was the CLARITY trial?
The CLARITY trial was a randomized,double-blind study that compared Cladribine to a placebo. It involved 1326 patients with active and highly active RRMS. Patients were given either 3.5 mg/kg or 5.25 mg/kg doses of cladribine or a placebo. It was found that there was a 58% reduction in the average annual relapse rate in patients who took cladribine. 80% of patients had no relapses, and MRI scans showed that patients who took cladribine developed 7.5 times fewer new brain lesions than those receiving a placebo.
What is NICE’s role in Cladribine’s availability?
NICE (National Institute for Health and Care Excellence) has issued guidance recommending cladribine for adults in England with RRMS. This recommendation broadens access to a larger patient population.
How many people are expected to benefit from NICE’s updated proposal?
Approximately 2,000 individuals are expected to benefit within the next 3 years from NICE’s updated proposal.
Summary of Cladribine (mavenclad)
| Feature | Description |
| —————————- | ————————————————————————————————————————- |
| drug Name | Cladribine (Mavenclad) |
| Indication | Relapsing-Remitting Multiple Sclerosis (RRMS) |
| Administration | Oral tablet, at-home |
| Dosing Schedule | 20 days of dosing over 4 years |
| Mechanism of Action | Targets T and B cells to reduce myelin sheath damage |
| Relapse Reduction | 58% reduction in average annual relapse rate (CLARITY trial) |
| Impact on Brain Lesions | 7.5 times fewer new brain lesions compared to placebo (CLARITY trial) |
| Pregnancy Planning | Safe to conceive in years 3 and 4 of treatment; 6 months after final course |